UBS Maintains Buy on Eli Lilly, Raises Price Target to $1425

Benzinga Newsdesk www.benzinga.com Positive 84.9%

Neg 0% Neu 0% Pos 84.9%

UBS analyst Michael Yee maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1250 to $1425.

Comments

No comments yet. Be the first!